24/7 Market News Snapshot 11 July, 2025 – Dare Bioscience, Inc. Common Stock (NASDAQ:DARE)

July 11, 2025

DENVER, Colo., 11 July, 2025 (www.247marketnews.com) – (NASDAQ:DARE) are discussed in this article.
Daré Bioscience, Inc. (NASDAQ:DARE), a prominent biopharmaceutical company focused on enhancing women’s health, has recently secured a significant non-dilutive funding installment of $6 million, part of its ongoing multi-year grant agreement. This financial boost is aimed at advancing DARE-LARC1, an innovative long-acting reversible contraceptive that employs Daré’s intelligent drug delivery system (DARE-IDDS). This funding increment raises the total received to approximately $37.8 million, part of a broader commitment of up to $49 million to support nonclinical development, Investigational New Drug (IND)-enabling studies, and to facilitate the submission of an IND to the U.S. Food and Drug Administration (FDA).

DARE-LARC1 is designed to deliver levonorgestrel through a next-generation programmable device, offering a promising solution that could revolutionize contraceptive management by minimizing the necessity for daily dosing and enhancing user adherence. Sabrina Martucci Johnson, the President and CEO of Daré Bioscience, noted the significance of this funding milestone, highlighting its potential to accelerate the development of what is deemed one of the most promising smart drug delivery technologies currently in progress. She emphasized its dual purpose of expanding reproductive health solutions while establishing a versatile platform capable of addressing numerous chronic conditions that require precise dosing and long-term management.

Amid a current bearish trading environment, with Daré’s stock trading at $2.273, reflecting a decline from the previous close, investor confidence remains critical. The robust trading volume of 4.86 million shares speaks to heightened interest, likely stemming from reactions to developments in the company’s innovative pipeline. As Daré explores strategic partnerships to broaden the reach of the DARE-IDDS platform, it positions itself to address a variety of therapeutic areas, including obesity and diabetes, potentially reshaping the landscape of treatment options and enhancing patient experiences across multiple sectors.

Related news for (DARE)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.